secwatch.observer — SEC 8-K summary
======================================

Issuer:     PTC THERAPEUTICS, INC. (PTCT)
CIK:        0001070081
Form:       8-K
Filed at:   2026-02-12T23:59:59+00:00
Accession:  0001104659-26-014414
Event type: regulatory
Sentiment:  negative
Materiality: 0.85
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PTC Therapeutics withdraws Translarna NDA resubmission after FDA cites insufficient efficacy data
--------------------------------------------------------------------------------

- Withdrew NDA resubmission for Translarna (ataluren) for nonsense mutation Duchenne muscular dystrophy.
- FDA feedback indicated data unlikely to meet substantial evidence of effectiveness threshold.
- CEO Matthew Klein expressed disappointment after more than two decades of development efforts.
- No path to FDA approval for Translarna in the U.S. at this time.
- PTC Therapeutics (PTCT) shares potential negative impact from this regulatory setback.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1070081/000110465926014414/0001104659-26-014414-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1070081/000110465926014414/tmb-20260212x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-014414

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer